ArticleEXCLI journal2017
Cellular uptake and anti-tumor activity of gemcitabine conjugated with new amphiphilic cell penetrating peptides.
Article in EXCLI journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Design and optimization of PLGA-based gemcitabine nanocapsule for enhanced pancreatic cancer efficacy.Investigational new drugs · 2025Article
- Development and characterization of lung surfactant-coated polymer nanoparticles for pulmonary drug delivery.Biomaterials advances · 2023Article
- Cell-Penetrating Dabcyl-Containing Tetraarginines with Backbone Aromatics as Uptake Enhancers.Pharmaceutics · 2022Article
- Two Possible Strategies for Drug Modification of Gemcitabine and Future Contributions to Personalized Medicine.Molecules (Basel, Switzerland) · 2022Review
- Recent Advances and Trends in Chemical CPP-Drug Conjugation Techniques.Molecules (Basel, Switzerland) · 2021Review
- Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.Journal of clinical medicine · 2021Review
- Effects of self-assembled cell-penetrating peptides and their nano-complexes on ABCB1 expression and activity.Iranian journal of basic medical sciences · 2021Article
- Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy.Molecules (Basel, Switzerland) · 2021Review
- Cytotoxicity and Immunogenicity Evaluation of Synthetic Cell-penetrating Peptides for Methotrexate Delivery.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells.Advanced pharmaceutical bulletin · 2020Article
- Development of Liposomal Gemcitabine with High Drug Loading Capacity.Molecular pharmaceutics · 2019Article
- pH-sensitive doxorubicin-loaded polymeric nanocomplex based on β-cyclodextrin for liver cancer-targeted therapy.International journal of nanomedicine · 2019Article
- Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications.Theranostics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gemcitabine (Gem) is used as a single agent or in combination with other anticancer agents to treat many types of solid tumors. However, it has many limitations such as a short plasma half-life, dose-limiting toxicities and drug resistance. Cell-penetrating peptides (CPPs) are short peptides which may deliver a large variety of cargo molecules into the cancerous cells. The current study was designed to evaluate the antiproliferative activity of gemcitabine chemically conjugated to CPPs. The peptides were synthesized using solid phase synthesis procedure. The uptake efficiency of CPPs into cells was examined by flow cytometry and fluorescent microscopy. The synthesized peptides were chemically conjugated to Gem and the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.